目的 探讨鼻渊舒口服液联合头孢克肟治疗慢性鼻窦炎的临床疗效。方法 选取2021年5月—2022年4月长江航运总医院收治的168例慢性鼻窦炎患者，按随机数字表法将所有患者分为对照组和治疗组，每组各84例。对照组口服头孢克肟胶囊，100 mg/次，2次/d。治疗组在对照组基础上口服鼻渊舒口服液，10 mL/次，3次/d。两组均连续治疗2周。观察两组临床疗效，比较治疗前后两组患者相关量表[鼻腔鼻窦结局测试-20（SNOT-20）评分、主观病情视觉模拟量表（VAS）评分、Lund-Mackay评分、Lund-Kennedy评分、36项健康调查简表（SF-36）]及血清肿瘤坏死因子-α（TNF）-α、白细胞介素-12（IL-12）、超敏C反应蛋白（hs-CRP）、转化生长因子-β1（TGF-β1）水平。结果 治疗后，治疗组总有效率是95.24%，显著高于对照组的85.71%（P＜0.05）。治疗后，两组SNOT-20中鼻部症状评分、睡眠障碍评分、相关症状评分、情感结局评分和总分均较治疗前显著降低（P＜0.05）；且均以治疗组下降更显著（P＜0.05）。治疗后，两组主观病情VAS评分、Lund-Mackay评分、Lund-Kennedy评分均显著下降，SF-36总分均显著增加（P＜0.05）；且均以治疗组改善更显著（P＜0.05）。治疗后，两组血清TNF-α、IL-12、hs-CRP、TGF-β1水平较治疗前均显著下降（P＜0.05）；且均以治疗组降低更显著（P＜0.05）。结论 鼻渊舒口服液联合头孢克肟治疗慢性鼻窦炎的整体疗效确切，能明显缓解患者症状，减轻病情严重程度，提高生活质量，并能有效下调血清TNF-α、IL-12、hs-CRP、TGF-β1水平，且安全性好。

Objective To investigate the clinical efficacy of Biyuanshu Oral Liquid combined with cefixime in treatment of chronic sinusitis. Methods A total of 168 patients with chronic sinusitis admitted to General Hospital of The Yangtze River Shipping from May 2021 to April 2022 were selected and divided into control group and treatment group according to random number table method, with 84 cases in each group. Patients in the control group were po administered with Cefixime Capsules, 100 mg/time, twice daily. Patients in the treatment group po administered with Biyuanshu Oral Liquid on the basis of the control group, 10 mL/time, 3 times daily. Both groups were treated continuously for 2 weeks. The clinical curative effects of the two groups were observed, and the related scales [Nasal and Sinus Outcome Test-20 (SNOT-20), Visual Analogue Scale (VAS), Lund-Mackay, Lund-Kennedy, 36-item Health Survey Short Form (SF-36)] score and serum tumor necrosis factor (TNF)-α, interleukin (IL)-12, high-sensitivity C-reactive protein (hs-CRP), transforming growth factor beta 1 (TGF) -β1) level before and after the treatment were compared. Results After treatment, the total effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (85.71%, P < 0.05). After treatment, nasal symptom score, sleep disorder score, related symptom score, emotional outcome score and total score of SNOT-20 in two groups were significantly decreased compared with before treatment (P < 0.05). The decrease was more significant in treatment group (P < 0.05). After treatment, the subjective VAS score, Lund-Mackay score, and Lund-Kennedy score were significantly decreased, and the total score of SF-36 was significantly increased in both groups (P < 0.05). The improvement was more significant in treatment group (P < 0.05). After treatment, serum levels of TNF-α, IL-12, hs-CRP, and TGF-β1 in two groups were significantly decreased compared with before treatment (P < 0.05). The decrease was more significant in treatment group (P < 0.05). Conclusion Biyuanshu Oral Liquid combined with cefixime has a definite overall curative effect in treatment of chronic sinusitis, and can significantly relieve the symptoms of patients, reduce the severity of the disease, improve the quality of life, and can effectively down-regulate serum TNF-α, IL-12, hs-CRP, the expression level of TGF-β1, and the safety is good.

R987

武汉市卫生健康科研基金资助项目（WX19D58）